After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price ...

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...